Andrew S. Brohl

机构：University of South Florida, Moffitt Cancer Center · ORCID：0000-0002-0071-0534

发表论文 330 篇 · 总被引 5783 次 · h-index 33

代表论文

The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study. (2026 · Journal of Clinical Oncology · 被引 3)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases. (2026 · Journal of Clinical Oncology · 被引 1)
MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma. (2026 · Journal of Clinical Oncology · 被引 1)
Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting (2026 · JCO Oncology Practice)
Supplemental Figure 4 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0 (2026)
Supplemental Figure 1 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0 (2026)